LB Pharmaceuticals — Third Quarter 2026 Earnings Summary

Financial Performance:

• Research and development expenses were $51.5 million for the three months ended September 30, 2026, compared to $2.4 million for the same period in 2025; for the nine months ended September 30, 2026, expenses were $110.3 million compared to $8.3 million in 2025.
• General and administrative expenses were $11.0 million for the three months ended September 30, 2026, compared to $2.8 million in 2025; for the nine months ended September 30, 2026, expenses were $28.2 million compared to $8.3 million in 2025.
• Net loss was $59.1 million for the three months ended September 30, 2026, compared to $3.6 million in 2025; for the nine months ended September 30, 2026, net loss was $129.7 million compared to $13.7 million in 2025.
• Net loss per share (basic and diluted) was $(1.79) for the three months ended September 30, 2026, compared to $(0.61) in 2025; for the nine months ended September 30, 2026, net loss per share was $(4.25) compared to $(6.26) in 2025.
• Cash, cash equivalents, and short-term investments totaled $403.8 million as of September 30, 2026, up from $295.2 million as of December 31, 2025.
• Total assets were $453.4 million as of September 30, 2026, compared to $312.9 million as of December 31, 2025.
• Total liabilities were $35.7 million as of September 30, 2026, compared to $11.6 million as of December 31, 2025.
• Total stockholders' equity was $417.6 million as of September 30, 2026, compared to $301.3 million as of December 31, 2025.

Guidance and Future Outlook:

• Topline data from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia is expected in the first half of 2027.
• A pre-New Drug Application meeting with the FDA is expected to be scheduled in the second half of 2027 following the NOVA-2 topline data.
• An update regarding a potential trial design for predominantly negative symptoms of schizophrenia is expected in the first quarter of 2027.
• Topline data from the Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar 1 depression is expected in the first quarter of 2028.
• Initiation of the Phase 2 trial for adjunctive treatment of MDD is expected in early 2027, with topline data expected in the first half of 2029.
• The company expects its current cash position to fund operations beyond the second quarter of 2029.

Business Segments and Product Lines:

• LB-102 is an investigational benzamide antipsychotic in late-stage development for schizophrenia, bipolar depression, major depressive disorder, and other brain disorders.
• Enrollment in the Phase 3 NOVA-2 trial for acute schizophrenia continues to progress strongly.
• The 52-week open-label safety and tolerability trial (NOVA-3) for stable schizophrenia continues to enroll patients who completed NOVA-2 as well as de novo patients.
• The Phase 2 ILLUMINATE-1 trial for bipolar 1 depression continues to enroll patients.
• The company is pursuing expansion opportunities for LB-102 into negative symptoms of schizophrenia and Alzheimer's disease psychosis/agitation.
• Four posters highlighting preclinical data on LB-102's bimodal mechanism of action were presented at the 39th ECNP Congress in October 2026.

Market and Competitive Landscape:

• LB-102 has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
• The company positions LB-102 as a potential branded antipsychotic of choice with a differentiated profile balancing efficacy, tolerability, and simplicity of use.
• LB-102 demonstrated statistically significant benefit versus placebo in a Phase 2 trial for acute schizophrenia, including rapid onset of effect at week 1.
• The company faces competition from third parties developing products for similar uses, as noted in risk factors.

Risks and Challenges:

• The company has a limited operating history and has incurred historical losses.
• Success is dependent on the ability to obtain regulatory approval and successfully commercialize LB-102.
• Risks include potential delays in initiating, enrolling, or completing clinical trials.
• The company faces risks related to obtaining, maintaining, and protecting intellectual property.
• The company is dependent on third parties for manufacturing, clinical trials, and preclinical studies.
• There is a risk that actual results may differ materially from forward-looking statements regarding clinical timelines and cash runway.

Management Commentary and Tone:

• CEO Heather Turner stated the company is "exceptionally well positioned" to maximize the potential of LB-102 due to a strong balance sheet and cash runway.
• The company strengthened its leadership team with the appointment of Dr. Susan G. Kozauer as Chief Medical Officer and Joseph Miller as Chief Financial Officer.
• Management highlighted the R&D Day event as evidence of LB-102's potential to become a mainstay of psychiatric practice.
• The tone reflects confidence in the clinical program's progress and the ability to fund operations through multiple clinical milestones.

Other Key Points:

• In July 2026, the company completed a private placement of $150.0 million, with net proceeds of approximately $140.9 million after fees and expenses.
• Proceeds from the private placement are intended to fund the expansion of LB-102 into new indications and for general corporate purposes.
• The company hosted an R&D Day in October 2026 featuring Dr. Roger McIntyre to discuss LB-102's mechanism of action and pre-commercial planning.
• The company is building a pipeline leveraging the broad therapeutic potential of LB-102 across a wide variety of brain disorders.